Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
25 hedge funds and large institutions have $9.29M invested in Amplify Treatments, Testing and Advancements ETF in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
14% more funds holding
Funds holding: 22 → 25 (+3)
6% more capital invested
Capital invested by funds: $8.79M → $9.29M (+$497K)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$756K |
| 2 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$443K |
| 3 |
G
Gainplan
Bloomfield Hills,
Michigan
|
+$428K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
+$385K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.59M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$712K |
| 3 |
Goldman Sachs
New York
|
-$399K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$128K |
| 5 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$80K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| – | +$37 | +1 | New |
|
GERM Hedge Fund Activity: Q2 2021 in Review
25 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q2 2021, worth a combined $9.29M — up 5.6% from $8.79M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GERM positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was LPL Financial, adding an estimated $756K. The largest seller was Jane Street, cutting an estimated $1.59M.
- 25 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q2 2021, up from 22 in Q1 2021.
- Funds reported $9.29M of Amplify Treatments, Testing and Advancements ETF stock for Q2 2021, up 5.6% quarter-over-quarter.
- 4 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q2 2021 and 1 closed out, a net change of +3 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q2 2021 was LPL Financial, an estimated $756K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q2 2021 was Jane Street, an estimated $1.59M sold.
Based on aggregated 13F filings for Q2 2021.